Engineering multi-specific antibodies against HIV-1

Ibalizumab: First Global Approval

(2018) Anthony Markham   DRUGS

eCD4-Ig Variants That More Potently Neutralize HIV-1

(2018) Ina Fetzer et al.   JOURNAL OF VIROLOGY

Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity

(2018) James J. Steinhardt et al.   Nature Communications

Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody

(2018) Young D. Kwon et al.   Cell Reports

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections

(2018) Kshitij Wagh et al.   PLoS Pathogens

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

(2018) Brinda Emu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

(2017) Asad Bashey et al.   JOURNAL OF CLINICAL ONCOLOGY

The making of bispecific antibodies

(2017) Ulrich Brinkmann et al.   mAbs

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

(2017) Marina Caskey et al.   NATURE MEDICINE

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

(2017) Ling Xu et al.   SCIENCE

Prospects for passive immunity to prevent HIV infection

(2017) Lynn Morris et al.   PLOS MEDICINE

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency

(2016) Stylianos Bournazos et al.   CELL

Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity

(2016) Yaoxing Huang et al.   CELL

HIV-Host Interactions: Implications for Vaccine Design

(2016) Barton F. Haynes et al.   Cell Host & Microbe

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

(2016) M. Bacac et al.   CLINICAL CANCER RESEARCH

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

(2016) Jörg T Regula et al.   EMBO Molecular Medicine

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth

(2016) Jinghe Huang et al.   IMMUNITY

Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies

(2016) Ruijiang Song et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design

(2016) Young D. Kwon et al.   JOURNAL OF VIROLOGY

CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications

(2016) Anke Steinmetz et al.   mAbs

Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1

(2016) Weizao Chen et al.   mAbs

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

(2016) P. Bru nker et al.   MOLECULAR CANCER THERAPEUTICS

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

(2016) Kshitij Wagh et al.   PLoS Pathogens

Intra-Spike Crosslinking Overcomes Antibody Evasion by HIV-1

(2015) Rachel P. Galimidi et al.   CELL

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

(2015) J. E. Ledgerwood et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization

(2015) M. Asokan et al.   JOURNAL OF VIROLOGY

New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency

(2015) Nicole A. Doria-Rose et al.   JOURNAL OF VIROLOGY

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

(2015) Marina Caskey et al.   NATURE

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges

(2015) Matthew R. Gardner et al.   NATURE

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

(2015) Rebecca M. Lynch et al.   Science Translational Medicine

Structural Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gp120 Interface on Intact HIV-1 Env Trimers

(2014) Claudia Blattner et al.   IMMUNITY

Rational Design and Characterization of the Novel, Broad and Potent Bispecific HIV-1 Neutralizing Antibody iMabm36

(2014) Ming Sun et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo

(2014) R. S. Rudicell et al.   JOURNAL OF VIROLOGY

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

(2014) Nicole A. Doria-Rose et al.   NATURE

Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex

(2014) Devin Sok et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent HIV-1 Inhibitors Based on Single Human CD4 and Antibody Domains

(2013) W. Chen et al.   JOURNAL OF VIROLOGY

Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1–neutralizing activity

(2013) Ruijiang Song et al.   NATURE BIOTECHNOLOGY

Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1

(2013) C. S. Pace et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope

(2012) Craig S. Pace et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

(2012) Jinghe Huang et al.   NATURE

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

(2012) H. Mouquet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab

(2011) J. Toma et al.   JOURNAL OF VIROLOGY

Broad neutralization coverage of HIV by multiple highly potent antibodies

(2011) Laura M. Walker et al.   NATURE

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

(2011) W. Schaefer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design

(2011) R. Diskin et al.   SCIENCE

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

(2011) J. F. Scheid et al.   SCIENCE

Epitope Mapping of Ibalizumab, a Humanized Anti-CD4 Monoclonal Antibody with Anti-HIV-1 Activity in Infected Patients

(2010) R. Song et al.   JOURNAL OF VIROLOGY

Bispecific antibodies for cancer therapy

(2010) Patrick Chames et al.   mAbs

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

(2010) Hugo Mouquet et al.   NATURE

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

(2010) T. Zhou et al.   SCIENCE

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

(2010) X. Wu et al.   SCIENCE

Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody

(2010) Michael M. Freeman et al.   STRUCTURE

Functional Characterization of N297A, A Murine Surrogate for low-Fc Binding Anti-Human CD3 Antibodies

(2009) Debra T. Chao et al.   IMMUNOLOGICAL INVESTIGATIONS

An Unfolded CH1 Domain Controls the Assembly and Secretion of IgG Antibodies

(2009) Matthias J. Feige et al.   MOLECULAR CELL

Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10

(2009) J. S. Klein et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Design of therapeutic proteins with enhanced stability

(2009) N. Chennamsetty et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

(2009) L. M. Walker et al.   SCIENCE

Antiviral Activity of Single‐Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV‐Infected Adults

(2008) Jeffrey M. Jacobson et al.   JOURNAL OF INFECTIOUS DISEASES

Molecular architecture of native HIV-1 gp120 trimers

(2008) Jun Liu et al.   NATURE